ClinicalTrials HQ

Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

Active, not recruiting · NCT06109181 · Registry updated 2025-11-12
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Gene Therapy for ACM Due to a PKP2 Pathogenic VariantCardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Death, Death, Sudden, Death, Sudden, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arrhythmogenic right ventricular cardiomyopathy, cardiac arrest, cardiomyopathy, cardiovascular disorder, congenital heart disease, heart disorderActive, not recruitingPhase 1 / Phase 22025-11-12NCT06109181

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Lexeo Therapeutics7

5 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Johns Hopkins UniversityBaltimoreUnited States150
Medical University of South CarolinaCharlestonUnited States628
Stanford UniversityStanfordUnited States213
University of MichiganAnn ArborUnited States538
University of RochesterRochesterUnited States360